Current Clinical Controversies and Promising Therapeutic Strategies in Advanced Prostate Cancer

A Live Clinical Investigator Think Tank

TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

OVERVIEW OF ACTIVITY
Cancer of the genitourinary system affects hundreds of thousands of individuals within the United States each year and accounts for almost 30% of all newly diagnosed tumors in humans. Tumors of the prostate are among the most prevalent and thus a topic of extensive ongoing clinical research. Consequently, the management of prostate cancer is continuously in a state of evolution, necessitating rapid and consistent access to learning opportunities for medical oncologists, radiation oncologists, urologists and other healthcare providers who treat the disease. These proceedings from an interactive CME symposium held during the 2013 Genitourinary Cancers Symposium offer medical professionals a multifaceted educational experience focused specifically on the current treatment of prostate cancer.

LEARNING OBJECTIVES
• Review the known efficacy and safety data related to radium-223 chloride in patients with skeletal metastases in preparation for its potential approval.
• Recall existing and emerging research information demonstrating the impact of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-naïve or pretreated castration-resistant prostate cancer, and use this information to guide treatment planning for these patients.
• Recognize the unique patterns of response with available and emerging immunotherapeutic strategies, and effectively counsel patients considering these treatments.
• Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutics, chemotherapeutics and secondary hormonal agents for patients with metastatic prostate cancer.
• Explore the emerging data and active research evaluating novel agents in the setting of advanced prostate cancer in order to prioritize clinical trial opportunities for appropriate patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GUCancers13/ThinkTank/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Daniel J George, MD
Associate Professor of Medicine and Surgery
Director of Genitourinary Oncology Program
Duke Cancer Institute
Durham, North Carolina

ResearchToPractice.com/GUCancers13/ThinkTank/Video
Advisory Committee: Aveo Pharmaceuticals, Dendreon Corporation, Medivation Inc, Pfizer Inc, Sanofi, Via met Pharmaceuticals Inc; Consulting Agreements: Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Exelixis Inc, Genentech BioOncology, Medivation Inc, Molecular Insight, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi, Teva Oncology; Contracted Research: Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Dendreon Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

Robert Dreicer, MD, MS
Chairman, Department of Solid Tumor Oncology
Taussig Cancer Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio


A Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana


Celestia S Higano, MD
Professor of Medicine and Urology
University of Washington School of Medicine
Member, Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington


Christopher J Logothetis, MD
Chairman/Professor, Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Paid Research: Dendreon Corporation, Johnson & Johnson Pharmaceuticals.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Algeta US/Bayer HealthCare Pharmaceuticals, Astellas/Medivation Inc, Dendreon Corporation, Millennium: The Takeda Oncology Company and Teva Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: May 2013
Expiration date: May 2014
SELECT PUBLICATIONS

George


Dreicer

Efstathiou E et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. Genitourinary Cancers Symposium 2011;Abstract 4501.


Sartor
Bruland ØS et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities? *Clin Cancer Res* 2006;12(20 Pt 2):6250s-7s.


Higano

Higano CS et al. Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. *Proc ASCO* 2010;Abstract 4550.


Small EJ et al. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. *Proc ASCO* 2011;Abstract 4661.

Logothetis


Tzelepi V et al. Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel. *Proc ASCO* 2010;Abstract 4663.